AI Science Tracker
EN

ESPCI Paris

1 discovery from 2025

Discoveries

Model-designed mutation paths switched WW-domain binding specificity

Source check: Source checked. Not independent scientific confirmation.

Finding: The first public preprint appeared on bioRxiv on 2025-12-10. Its reviewed version reports that designed WW-domain mutational paths largely retained binding, while the same mutations introduced in scrambled order disrupted function. The eLife reviewed-preprint v1 (2026-04-09) later quantified binding for 54 of 58 tested designs and described cross-reactive intermediates on some specificity transitions. In-vitro binding to representative peptides does not establish in-vivo function or generalize to all WW domains.

Technology: Unsupervised restricted Boltzmann machine

Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.

AI contribution
The learned sequence model sampled intermediate sequences and mutation orders between natural WW domains with different binding specificities.
Test and result
The primary version history identifies a bioRxiv preprint posted 2025-12-10 before the eLife reviewed-preprint v1 dated 2026-04-09. The eLife v1 reports that 54 of 58 tested sequences designed along model-sampled WW-domain paths bound at least one representative peptide class; variants with the same mutations in scrambled order were nonfunctional. The specific 54/58 count is attributed to the eLife v1, not assumed for the earlier version.
Limitation / still unknown
In-vitro binding to representative peptides does not establish in-vivo function or generalize to all WW domains.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://www.biorxiv.org/content/10.64898/2025.12.08.693000v1 · https://elifesciences.org/reviewed-preprints/110491v1

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 22 Nov 2026. Review scope: Read the eLife reviewed-preprint v1 Methods and Results and version history; checked the version history identifying the earlier 2025-12-10 bioRxiv preprint and author affiliations on the eLife article information page..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.